We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 105% below its sector, cheaper than its peers on earnings.
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. These solutions cater to a range of applications, including the identification of infectious diseases, genetic profiling, and pathogen detection. At the core of their offerings is the proprietary Genedrive system, a compact polymerase chain reaction (PCR) technology. This advanced platform enables the rapid amplification and detection of nucleic acids from diverse biological samples, such as plasma, sputum, and buccal swabs. The Genedrive platform features several key diagnostic products: the Genedrive HCV ID Kit for qualitative Hepatitis C virus detection; the Genedrive BioPlex, designed for the quick identification of military biothreats from pathogens; and the Genedrive MT-RNR1-ID Kit, a rapid genetic test vital for emergency neonatal care. Complementing these is the Genedrive Connect app, an Android-based mobile application that streamlines data management and facilitates results transmission. Genedrive Plc serves the biotechnology and pharmaceutical sectors globally, with its reach extending throughout the United Kingdom, Europe, the United States, and other international regions. The company has also partnered with Beckman Coulter Life Sciences to automate laboratory PCR testing procedures for COVID-19.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save GDR.L and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
